The latest trend in treating hair loss may sound familiar — essentially, it's a repurposed drug first popularized in the ...

Pierre Noé, Stéphane Malhouitre, and Benoît Charbonnier, discuss phase change materials for reconfigurable photonic ...

For months, there have been rumblings online about Ozempic being linked to hair loss. But like Ozempic face, Ozempic butt, ...

Physicists at Washington University have forged ahead in the field of quantum mechanics by creating a new phase of matter ...

In December, in the REDEFINE 1 Phase 3 trial, CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and ...

(RTTNews) - Ascletis Pharma Inc. (ASCLF.PK) announced promising pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies conducted in Australia.

The company said a Phase 3 trial showed that after 68 weeks, those who took CagriSema achieved a weight loss of 15.7%, compared with a weight loss of 3.1% for those taking a placebo. Tomi Kilgore ...

In a phase 3 trial spanning 68 weeks ... If all adhered to the weekly treatment, CagriSema patients achieved 15.7% weight loss, compared to 3.1% with the placebo. Nearly 90% of CagriSema patients ...

Wednesday’s order from a three-judge panel of the 9th US Circuit Court of Appeals marked the first setback for Trump in this next phase of the legal clash.